(NASDAQ: PTCT) Ptc Therapeutics's forecast annual revenue growth rate of -20.36% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.11%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.31%.
Ptc Therapeutics's revenue in 2025 is $1,779,150,000.On average, 18 Wall Street analysts forecast PTCT's revenue for 2025 to be $141,869,434,935, with the lowest PTCT revenue forecast at $130,709,360,540, and the highest PTCT revenue forecast at $156,321,329,835. On average, 18 Wall Street analysts forecast PTCT's revenue for 2026 to be $70,921,871,339, with the lowest PTCT revenue forecast at $41,851,081,864, and the highest PTCT revenue forecast at $92,973,857,190.
In 2027, PTCT is forecast to generate $88,397,423,805 in revenue, with the lowest revenue forecast at $72,186,412,142 and the highest revenue forecast at $118,023,808,350.